CDK9 and cancer: In summary, our data demonstrate that simultaneous inhibition of CDK9 and the KRAS/MAPK pathway reciprocally strengthen the anticancer effect of each monotherapy in preclinical models of KRAS‐mutant cancers, including those with KRASi resistance.